PharmaShots | Incisive News in 3 Shots

Subscribe Now

Affimed

Affimed Secures the US FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Acimtamig and AlloNK Combination

Affimed Secures the US FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Acimtamig and AlloNK Combination

December 6, 2024

$Affimed’s AFM13 + AlloNK Receives the US FDA’s Fast Track Designation for Relapsed or Refractory Hodgkin Lymphoma$

Affimed’s AFM13 + AlloNK Receives the US FDA’s Fast Track Designation for Relapsed or Refractory Hodgkin Lymphoma

September 13, 2023

Affimed Reports First Patient Dosing of AFM28 in the P-I Study for the Treatment of CD123-Positive Acute Myeloid Leukemia

Affimed Reports First Patient Dosing of AFM28 in the P-I Study for the Treatment of CD123-Positive Acute Myeloid Leukemia

March 29, 2023

PharmaShots Interview: Affimed's Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020

PharmaShots Interview: Affimed's Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020

February 10, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us